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Abstract
D-Ribose, a pentose sugar, has shown to improve myocardial high-energy phosphate stores
depleted by ischemia. This study investigated the ability of D-Ribose with low dose dobutamine to
improve the contractile response of viable myocardium to dobutamine and to assess the efficacy
of D-ribose in reducing stress-induced ischemia. Twenty-six patients with ischemic cardiomyopathy
completed a two-day, randomized, double blind crossover trial comparing the effects of D-Ribose
and placebo on regional wall motion. On the first study day, either D-Ribose or placebo was infused
for 4.5 hours. Low (5 and 10 μ/kg/min) and subsequently, high (up to 50 μ/kg/min) dose dobutamine
echocardiography was then performed. On the second study day, patients crossed over to the
alternative article for a similar 4.5 hours infusion time period and underwent a similar evaluation.
The wall motion response during low dose dobutamine was the same with D-Ribose and placebo
in 77% of segments (203/263, Kappa = 0.37). In segments with discordant responses, more
segments improved with D-Ribose than with placebo (41 vs. 19 segments, p = 0.006). With high
dose dobutamine infusion, the wall motion response (ischemia vs. no ischemia) was the same with
D-Ribose and placebo in 83% of interpretable segments (301/363, kappa = 0.244). In segments with
discordant responses, there were more ischemic segments with placebo compared to D-Ribose
(36 vs. 26, p = 0.253). Nineteen patients developed ischemia during the dobutamine and placebo
infusion and 13 patients had ischemia during dobutamine and D-ribose infusion (p = 0.109). D-
Ribose improved contractile responses to dobutamine in viable myocardium with resting
dysfunction but had no significant effect in reducing the frequency of stress-induced wall motion
abnormalities.
Background
The maintenance of cellular integrity and contractility rely
on adequate levels of adenosine triphosphate (ATP). Myo-
cardial ischemia alters oxidative metabolism resulting in
lower tissue ATP levels along with an associated impair-
ment in contractile function [1,2]. The repletion of ATP
stores depends on the availability of the precursor phos-
phoribosyl-pyrophosphate (PRPP). D-Ribose (DR), a
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pentose monosaccharide, has been shown to accelerate
ATP repletion in the ischemic myocardium by promoting
the production of PRPP. In animal studies, DR enhanced
the repletion of ATP after global and regional ischemia,
resulting in an improvement in contractile function [3-7].
Pliml et al. showed that DR reduced the frequency of
stress-induced ST segment depression in patients with sta-
ble coronary arterial disease [8]. The effect of DR in
ischemic contractile dysfunction in patients is unknown.
The anti-ischemic effects of DR were tested during low
and high dose dobutamine infusion in patients with
ischemic left ventricular systolic dysfunction. Low dose
dobutamine infusion is widely used for the assessment of
viability in segments with resting dysfunction due to
hibernating or stunned myocardium [9]. The lack of a
contractile response with dobutamine in viable segments
may be due to the tenuous oxygen supply-demand bal-
ance that exists in segments supplied by severely diseased
vessels [10,11]. Viable myocardium may fail to contract
during low dose dobutamine stimulation if there is an
increase in oxygen demand due to existing native vascular
ischemia. D-Ribose may improve ATP levels in a setting
where inotropic infusion increases oxygen demand. The
effect of DR in preventing or reducing stress-induced con-
tractile dysfunction was also assessed during high dose
dobutamine infusion.
Methods
Patient Selection
Potential subjects for the study were screened by review of
echocardiograms performed for clinical purposes at Indi-
ana University Medical Center. Patients with (1) left ven-
tricular dysfunction (ejection fraction < 50%), (2) resting
regional wall motion abnormalities, and (3) coronary
artery disease were eligible for the study. Coronary artery
disease was documented by one or more of the following:
coronary angiography, stress testing showing ischemia, or
previous myocardial infarction. Only patients with stable
symptoms were included. Patients requiring daily or fre-
quent adjustment of vasoactive medications were
excluded as well as those who had myocardial infarction
or an episode of unstable angina less than 5 days before
enrollment. Subjects having diabetes mellitus requiring
insulin or oral hypoglycemic medications were also
excluded on the basis of studies showing that plasma glu-
cose levels may decline with DR administration [12].
Twenty-eight patients (25 men, 3 women) with a mean
age of 56 ± 12 years were enrolled in this study. All
patients had reduced left ventricular systolic function
(mean ejection fraction 30 ± 8%, range 16 to 49%).
Twenty-five patients had a prior history of myocardial inf-
arction. Twenty-one patients had stable angina pectoris
and were receiving 1 or more medications, including
nitrates, beta-antagonists, and calcium channel antago-
nists. Coronary artery disease (≥ 50% diameter stenosis of
a major coronary artery) was documented by angiography
in 25 patients. Of the 24 patients with recent angiograms,
12 had three vessel disease, 10 had two vessel disease, and
2 had single vessel disease.
Study Protocol
This randomized double-blind placebo-controlled trial
was approved by the Indiana University Institutional
Review Board and informed consent was obtained from
all patients. The study was performed at the Clinical
Research Center of Indiana University Hospital. The Uni-
versity Hospital Pharmacy performed the randomization
and blinding of each test article. D-Ribose was adminis-
tered as a 10% solution in water at 180 mg/kg/hr, a dose
which has previously shown in humans to be without
adverse effects [13].
On Day 1, patients underwent an initial physical exami-
nation and a baseline echocardiogram. Peripheral intrave-
nous catheters were placed and the randomized test article
(DR or placebo) was infused along with a separate infu-
sion of D5W (1.8 ml/kg/hr) at 100 ml/hr as a mainte-
nance fluid. Four and one half hours following
commencement of the test article infusion, a second
echocardiogram was performed. After this imaging study,
dobutamine infusion was initiated. Echocardiograms
were acquired at low doses (5, 10 μg/kg/min) and at a
peak dose of up to 50 μ/kg/min. Upon completion of all
imaging, the infusion was terminated. Patients were
observed overnight in the Research Center and on Day 2
were crossed over to the alternate test article. The proce-
dures performed on Day 2 were the same as that of Day 1.
Patients were discharged to home after several hours of
observation following completion of the procedures on
Day 2.
Dobutamine Stress Echocardiography
Dobutamine stress echocardiograms were obtained using
parasternal long and short axis and apical two and four
chamber views. Dobutamine was initially infused at 5 μg/
kg/min, increased to 10 μg/kg/min after 3 min and then
by 10 μg/kg/min increments every 3 min. Endpoints for
the infusion included: extensive new or worsening wall
motion abnormalities; chest pain, ≥ 2 mm ST segment
depression or elevation; significant adverse side effects,
arrhythmias or hypotension (defined by the supervising
physician);  ≥ 85% of the age-predicted maximal heart
rate, or at the maximal dose of 50 μg/kg/min. Intravenous
atropine was used in subjects who did not have substan-
tial increases in heart rate at the 30 μg/kg/min dose.
Echocardiographic images were digitally stored at rest, 5
and 10 μg/kg/min, and at peak dose.Cardiovascular Ultrasound 2009, 7:5 http://www.cardiovascularultrasound.com/content/7/1/5
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Myocardial wall motion and thickening were visually
assessed by the consensus of two investigators using a 16
segment model of the left ventricle and a previously
described scoring system [14]. Investigators were blinded
to the clinical data and test articles (DR or placebo). Each
dobutamine study arm was analyzed separately without
direct comparisons of Day 1 and Day 2 images. Segments
with a baseline score of ≥ 2.0 were considered to have rest-
ing dysfunction. Improvement in function by one grade
with low dose dobutamine was considered to be signifi-
cant. Stress-induced ischemia with high dose dobutamine
was defined by the development of a new wall motion
abnormality or worsening of a pre-existing wall motion
abnormality except for segments that were akinetic both
at rest and at low dose dobutamine.
Statistical Analysis
Data for heart rate, blood pressure, regional wall motion
scores and ejection fraction are expressed as the mean ±
one standard deviation (SD). Resting hemodynamic data
obtained with either DR or placebo were assessed with
paired t-tests. The changes in these parameters during
dobutamine infusion were compared using two-way
repeated measured ANOVA. A significant interaction term
indicated that the response to dobutamine was different
on DR compared to placebo. Agreement in myocardial
segmental responses to dobutamine + DR or dobutamine
+ placebo was evaluated by the Kappa statistic. The signif-
icance of differences in the response of individual patients
and myocardial segments to dobutamine + DR and dob-
utamine + placebo was determined by McNemar's test.
Categorical variables were analyzed by the Fisher exact
test. A p value < 0.05 was considered significant.
Results
Of the 28 patients enrolled in the study, two failed to
complete the two day study protocol. One patient devel-
oped chest pain during infusion of the placebo on Day 2.
The chest pain was relieved with sublingual nitroglycerin
and dobutamine echocardiography was not performed.
The following day, coronary angiography demonstrated
obstruction of the posterolateral branch of the right coro-
nary artery which was treated with angioplasty. The sec-
ond patient developed chest pain on the first study day
during infusion of dobutamine and placebo. The patient
was taken for urgent coronary angiography with angi-
oplasty of a severely stenotic diagonal artery.
Hemodynamics
In the 26 patients who completed both study days, resting
left ventricular ejection fraction was similar between DR
and placebo (31 ± 8%, 30 ± 8%, respectively, p = 0.945).
The peak dose of dobutamine used was 42 ± 11 ug/kg/
min in the placebo group and 42 ± 8 uk/kg/min in the DR
patients (p = 0.770). Hemodynamic measurements in
both DR and placebo groups are shown in Table 1. There
was a trend towards a higher rate pressure product at rest
in the placebo group (p = 0.09). The hemodynamic
response to both low and high doses of dobutamine was
similar in both the DR and placebo groups. Rate pressure
product increased significantly from rest to low dose dob-
utamine infusion (10 ug/kg/min) in both the DR (p =
0.001) and the placebo groups (p = 0.004). The increase
in rate pressure product at 10 ug/kg/min of dobutamine
was similar between the two test articles (p = 0.330) and
the peak (high dose dobutamine) rate pressure product
was also similar between placebo and DR (16,060 ± 5050
vs. 15,540 ± 4560, respectively, p = 0.569).
Regional Function Assessment at Low Dose Dobutamine
The results of DR +low dose dobutamine and placebo +
low dose dobutamine on a per patient basis are repre-
sented in Table 2. Improvement in at least one myocardial
segment was required for a patient to be considered as
having improvement in regional wall motion. The overall
agreement between DR and placebo was 65% (17/26),
kappa = .22. In the 9 patients with discordant findings, 6
had improvement with DR + dobutamine vs. 3 with pla-
Table 1: Hemodynamic Parameters at Rest and During Dobutamine (Dob) Infusion
HR SBP DBP HR × BP HR SBP DBP HR × BP
AM 68 ± 11 123 ± 19 74 ± 13 8390 ± 2040 AM 71 ± 13 122 ± 13 77 ± 10 8640 ± 2240
PM 67 ± 13 116 ± 14 71 ± 9 7860 ± 1990 PM 69 ± 14 125 ± 20 72 ± 10 8690 ± 2220
Dob Rest 64 ± 14 116 ± 15 67 ± 11 7500 ± 1900 Dob Rest 65 ± 13 123 ± 18 73 ± 12 8090 ± 2110
Dob 5 μg 66 ± 15 116 ± 15 66 ± 11 7720 ± 2030 Dob 5 μg 68 ± 14 121 ± 19 70 ± 15 8320 ± 2390
Dob 10 μg 74 ± 17 118 ± 15 65 ± 10 8750 ± 2480 Dob 10 μg 75 ± 20 122 ± 20 70 ± 13 9300 ± 3540
Peak 120 ± 18 121 ± 19 62 ± 11 14570 ± 3070 Peak 119 ± 24 130 ± 24 67 ± 14 15460 ± 4780Cardiovascular Ultrasound 2009, 7:5 http://www.cardiovascularultrasound.com/content/7/1/5
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cebo + dobutamine (p = 0.508). The segment by segment
correlation between the results of DR + dobutamine and
placebo + dobutamine is shown in Table 3. Overall agree-
ment was 77% (203/263), kappa = 0.37. In 60 segments
with discordant responses, an improvement in wall
motion during low dose dobutamine infusion occurred
more frequently with DR than with placebo (41 vs. 19 seg-
ments, respectively, p = 0.006).
Regional Function with High Dose Dobutamine Stress
The results with high dose DR + dobutamine and placebo
+ dobutamine on a per patient basis are shown in Table 4.
The overall agreement between DR and placebo was 62%
(16/26), kappa = 0.23. In the 10 patients with discordant
findings, 8 patients developed ischemic wall motion
abnormalities with placebo compared to 2 with DR (p =
0.109). The segment by segment correlation between dob-
utamine + DR or dobutamine + placebo is shown in Table
5 with an overall agreement of 83% (301/363), kappa =
0.24. In the 62 myocardial segments with discordant
results, there was no significant difference in the number
of ischemic segments with placebo vs DR infusion (36 vs
26 segments, respectively, p = 0.253).
Discussion
This pilot study revealed that intravenous DR improved
the contractile response of segments with resting dysfunc-
tion to low dose dobutamine infusion. DR did not signif-
icantly reduce the effects of stress-induced ischemia.
Efficacy of D-ribose with Low Dose Dobutamine
Myocardial ischemia depletes ATP stores. Adenosine tri-
phosphate stores normally regenerate slowly through a
salvage pathway that recycles nucleotide precursors [15].
D-ribose improves repletion of ATP stores by increasing
precursors of ATP. In animal models, the improvement of
ATP stores has been correlated with improvements in con-
tractile function.
In this study, DR improved the contractile response to
dobutmaine in myocardial segments with resting dysfunc-
tion. Viable segments with resting dysfunction are pre-
sumed to have repetitive stunning or a progressive
reduction in resting perfusion characterized as hiberna-
tion. Adenosine triphosphate stores are reduced in hiber-
nating myocardium [16,17]. Hibernating myocardial
segments are typically supplied by severely stenotic arter-
ies, which result in absent or nearly an absent perfusion
reserve. Therefore, oxygen supply-demand balance is ten-
uous. The administration of low dose dobutamine may
increase myocardial oxygen demand, which can further
deplete ATP stores, preventing or limiting any improve-
ment in regional contractility with inotropic stimulation
[18]. We found a small but significant increase in heart
rate – blood pressure product during low dose (10 μg/kg/
min) dobutamine infusion, reflecting an increase in myo-
cardial oxygen demand. In a previous study, low dose
dobutamine has been shown to worsen the reduction in
myocardial ATP levels in the presence of reduced resting
perfusion [19].
Table 2: Patients With and Without Improvement in Regional 
Wall Motion during Low Dose Dobutamine Infusion
Dob + DR
Yes No
Yes 13 3*
Dob + Placebo
No 6* 4
Dob = low dose dobutamine. *p = 0.508 that the frequency of 
improvement with Dob + DR is similar to Dob + placebo.
Table 3: Segments With and Without Improvement of Regional 
Wall Motion with Low Dose Dobutamine
Dob + DR
Yes No
Yes 31 19*
Dob + Placebo
No 41* 172
p* = 0.006 (frequency of improvement is the same with dobutamine + 
DR and dobutamine + placebo)
Table 4: Patients With and Without Stress-Induced Wall Motion 
Abnormalities
Dob + DR
Yes No
Yes 11 8*
Dob + Placebo
No 2* 5
*p = 0.109 (frequency of stress-induced wall motion abnormalities 
with Dob + DR is similar to that for Dob + placebo)
Table 5: Segments With and Without Stress-Induced Wall 
Motion Abnormalities
Dob + DR
Yes No
Yes 16 36*
Dob + Placebo
No 26* 285
p* = 0.253 (frequency of stress-induced wall motion abnormalities 
with Dob + DR is similar to that for Dob + placebo)Cardiovascular Ultrasound 2009, 7:5 http://www.cardiovascularultrasound.com/content/7/1/5
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Clinical Utility of D-Ribose and Low Dose Dobutamine 
Infusion
Our findings suggest potential uses of DR both as a diag-
nostic and a therapeutic agent. Low dose dobutamine
infusion is used as a diagnostic technique for the detec-
tion of viable myocardium in patients who are considered
candidates for coronary revascularization. This technique
may have reduced sensitivity in patients who have
reduced resting myocardial perfusion and hibernation
[10,14]. Underestimation of the presence or extent of via-
ble myocardium may lead to a decision not to perform
revascularization or in a delay in revascularization. Stud-
ies have shown that a delay in revascularization of hiber-
nating myocardium may lead to myocardial infarction
and cardiac death [20,21].
Low dose dobutamine infusion also remains as a thera-
peutic modality for short-term inotropic support for con-
gestive heart failure patients with low cardiac output;
however, the use of inotropics can be potentially harmful
[22,23]. Induction of arrhythmias or ischemia with ino-
tropic infusions may be the mediators of a poorer clinical
outcome. In a swine model of hibernation, Schulz, et al.
reported that low dose dobutamine administered for one
and a half hours produced a progressive reduction in ATP
levels and myocardial necrosis [19]. In rodent studies,
ATP stores and the magnitude of improvement in contrac-
tion with isoproterenol infusion declines with prolonged
administration of the catecholamine. D-Ribose been
shown to improve ATP stores and contractile function in
rats subjected to prolonged isoproterenol infusions [24].
D-Ribose has also been shown to reduce the frequency of
isoproterenol induced myocardial necrosis [25]. D-ribose,
by improving the contractile response to dobutamine,
may also permit the use of lower doses of dobutamine to
achieve the desired hemodynamic improvement in stroke
volume.
Efficacy of D-Ribose in Stress-Induced Ischemia
D-Ribose did not significantly reduce the frequency or
extent of myocardial ischemia during high dose dob-
utamine infusion. Heart rates and rate-pressure products
at peak stress were comparable between the infusions of
placebo and DR, suggesting that the level of stress was
similar. These preliminary findings suggest that DR may
not offer an adequate protection during acute ischemic
situations demanding marked increases in oxygen
demand. However, in our study, there was a trend towards
fewer patients having stress-induced ischemia with DR
compared to placebo. Furthermore, in our pilot study a
relatively brief (4.5 hour) infusion period of DR was used.
Restoration of normal myocardial ATP levels may require
at least 24 hours following a moderate ischemic episode
[26]. Pliml et al. showed that DR was effective in reducing
ischemic ST segmental changes during exercise testing
when given orally for 3 days before evaluation [8]. Our
results suggest that in patients who may have reduced ATP
levels from prolonged or repetitive episodes of ischemia,
an extended infusion period of DR may be required to
demonstrate efficacy for the prevention of stress-induced
ischemia.
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